SLRX: Salarius Pharmaceuticals, Inc. Stock

by  •  • Comments Off on SLRX: Salarius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.10
Enterprise Value ($M) -3.51
Book Value ($M) 5.29
Book Value / Share 1.23
Price / Book 0.40
NCAV ($M) 5.22
NCAV / Share 1.21
Price / NCAV 0.40

Profitability (mra)
Return on Invested Capital (ROIC) -2.25
Return on Assets (ROA) -1.25
Return on Equity (ROE) -2.26

Liquidity (mrq)
Quick Ratio 5.02
Current Ratio 5.02

Balance Sheet (mrq) ($M)
Current Assets 6.52
Assets 6.59
Liabilities 1.30
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -12.89
Net Income -12.54
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -12.85
Cash from Investing 0.00
Cash from Financing 6.64

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
10-27 13D Lee Elvin Sanghwan 6.09

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 3,649 8,771 41.60
2024-04-17 37,266 106,414 35.02
2024-04-16 2,320 20,980 11.06
2024-04-15 291 5,820 5.00

(click for more detail)

Similar Companies
SCLX – Scilex Holding Company SEEL – Seelos Therapeutics, Inc.
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SLS – SELLAS Life Sciences Group, Inc.
SMFL – Smart for Life, Inc.


Financial data and stock pages provided by
Fintel.io